surpass 2 tirzepatide Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Effect of tirzepatide versus insulin
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15








![UPDATE [March 7, 2025]: OFA takes tirzepatide case to appeals court as legal battle evolves](https://static.wixstatic.com/media/60489a_4574a8e7f0164cada274871fc8522841~mv2.png/v1/fill/w_1000,h_563,al_c,q_90,usm_0.66_1.00_0.01/60489a_4574a8e7f0164cada274871fc8522841~mv2.png)


















